Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
1993-1-22
|
| pubmed:abstractText |
During the last decade there has been a rapid progress in the development of new, much improved vaccines against cholera. These vaccines, which are given orally to stimulate the gut mucosal immune system, are based on either a combination of purified cholera toxin B (binding) subunit and killed cholera vibrios of Inaba and Ogawa serotypes and El Tor and classical biotypes (B subunit-whole cell vaccine, B-WC) or on a live attenuated mutant strain of Vibrio cholerae producing the B subunit (CVD 103-HgR). The safety of the oral B-WC cholera vaccine and the immunogenicity and protective efficacy of this vaccine against both cholera and diarrhoea caused by enterotoxigenic Escherichia coli have been extensively documented, e.g. in a large randomized, placebo-controlled field trial in 90,000 persons living in a cholera endemic area. The potential for inexpensive large-scale manufacturing of the B-WC vaccine has recently been much facilitated by the introduction of recombinant DNA technology for production of the B subunit component. This now gives promise that this vaccine could become a useful, cost-effective tool in future strategies to control cholera both in endemic situations and in relation to acute epidemic outbreaks.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholera Toxin,
http://linkedlifedata.com/resource/pubmed/chemical/Cholera Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Attenuated,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Inactivated,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0264-410X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
911-4
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1471411-Administration, Oral,
pubmed-meshheading:1471411-Adolescent,
pubmed-meshheading:1471411-Adult,
pubmed-meshheading:1471411-Bangladesh,
pubmed-meshheading:1471411-Child,
pubmed-meshheading:1471411-Child, Preschool,
pubmed-meshheading:1471411-Cholera,
pubmed-meshheading:1471411-Cholera Toxin,
pubmed-meshheading:1471411-Cholera Vaccines,
pubmed-meshheading:1471411-Female,
pubmed-meshheading:1471411-Follow-Up Studies,
pubmed-meshheading:1471411-Humans,
pubmed-meshheading:1471411-Male,
pubmed-meshheading:1471411-Vaccination,
pubmed-meshheading:1471411-Vaccines, Attenuated,
pubmed-meshheading:1471411-Vaccines, Inactivated,
pubmed-meshheading:1471411-Vaccines, Synthetic,
pubmed-meshheading:1471411-Vibrio cholerae
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
An oral B subunit: whole cell vaccine against cholera.
|
| pubmed:affiliation |
Department of Medical Microbiology and Immunology, University of Göteborg, Sweden.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|